Steven A. Carr
Steven Carr is director of the Proteomics Platform at the Broad Institute of MIT and Harvard. He is internationally recognized as a leader in the development of novel proteomics methods and in their application in biology and medicine.
Carr and his group collaborate with scientists across the Broad Institute, Harvard University, Harvard Medical School, and the 17 Harvard-affiliated hospitals. They apply state-of-the-art proteomics technology to address compelling questions in biology, chemistry, and clinical medicine.
Research in his lab focuses on detecting and quantifying modifications in the system of proteins in an organism, known as the proteome, as well as developing new technologies to quantify proteins in cells and biological fluids with a high degree of specificity. Carr and his team are also improving computational methods of analyzing data from mass spectrometers, which measure proteins and peptides, and in integrating that data with genomic data. His group has developed and applied systematic approaches for discovery of biomarkers, or molecular signatures in bodily fluids like blood. Those approaches ultimately could provide biomarkers for cancers, heart disease, infectious diseases, and metabolic disorders.
Before joining the Broad Institute in 2004, Carr held scientific positions in the pharmaceutical and biotechnology industries, including Director of Computational and Structural Sciences at GlaxoSmithKline Pharmaceuticals and Senior Director of Protein Science and Technology at Millennium Pharmaceuticals in Cambridge, Massachusetts. He has over 180 publications on the development and use of proteomics and biological mass spectrometry. He is an associate editor of Molecular and Cellular Proteomics, and he has served on the editorial boards of Analytical Chemistry and Protein Science, among others.
Carr received his B.S. from Union College and Ph.D. from MIT.